Nature Communications (Aug 2017)

Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms

  • Dae-Sun Kim,
  • Himika Dastidar,
  • Chunfen Zhang,
  • Franz J. Zemp,
  • Keith Lau,
  • Matthias Ernst,
  • Andrea Rakic,
  • Saif Sikdar,
  • Jahanara Rajwani,
  • Victor Naumenko,
  • Dale R. Balce,
  • Ben W. Ewanchuk,
  • Pankaj Tailor,
  • Robin M. Yates,
  • Craig Jenne,
  • Chris Gafuik,
  • Douglas J. Mahoney

DOI
https://doi.org/10.1038/s41467-017-00324-x
Journal volume & issue
Vol. 8, no. 1
pp. 1 – 13

Abstract

Read online

Oncolytic viruses (OV) and second mitochondrial activator of caspase (Smac)-mimetic compounds (SMC) synergistically kill cancer cells directly. Here, the authors show that SMC and OV therapies combination also synergize in vivo by promoting anticancer immunity through an increase in CD8+ T-cell response.